BioXcel Therapeutics reported that the European Patent Office granted the Company’s European Patent No. 3,562,486 on March 13, 2024. The 486 patent covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia. The patent encompasses a broad range of dosage forms, including films such as BXCL501 wafers, and tablets, at dexmedetomidine doses ranging from 3 mcg to 100 mcg.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BTAI:
- BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
- BioXcel Therapeutics price target lowered to $7 from $18 at Canaccord
- BioXcel Therapeutics price target lowered to $7 from $8 at BofA
- Options Volatility and Implied Earnings Moves Today, March 12, 2024
- BioXcel Therapeutics provides updates on clinical programs for BXCL501
